Bioventus (NASDAQ:BVS) Stock Rating Upgraded by Wall Street Zen

Key Points

• Bioventus has been upgraded to a "strong-buy" rating by analysts at Wall Street Zen, indicating increased confidence in the company's stock.
• The company's stock currently has a market capitalization of $568.41 million and a price-to-earnings ratio of -14.42.
• Despite recently posting earnings per share (EPS) of $0.21, Bioventus missed analysts' expectations by $0.01, reflecting some challenges in their financial performance.

Bioventus (NASDAQ:BVS - Get Free Report) was upgraded by Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report released on Saturday.

Bioventus Stock Performance

Shares of NASDAQ:BVS traded up $0.07 during trading on Friday, reaching $7.38. 124,604 shares of the company traded hands, compared to its average volume of 394,762. The company has a market cap of $606.19 million, a price-to-earnings ratio of 13.86 and a beta of 0.83. The company has a debt-to-equity ratio of 1.48, a quick ratio of 0.96 and a current ratio of 1.48. Bioventus has a 52 week low of $5.81 and a 52 week high of $14.38.

Bioventus (NASDAQ:BVS - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.21 earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.01). Bioventus had a negative net margin of 0.03% and a positive return on equity of 23.04%.

Bioventus Company Profile

Bioventus Inc a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.